New malaria vaccine trial aims to block the parasite at multiple stages

NCT ID NCT06958198

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new malaria vaccine designed to target the parasite at different stages of its life cycle. Researchers will give the vaccine to 56 healthy adults (18-35 years) and children (5-17 months) in Burkina Faso to check its safety and how well it triggers an immune response. The goal is to find a vaccine that could better protect against malaria.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institut de Recherche en Sciences de la Santé

    RECRUITING

    Siglé, Boulkiemdé Province, BP 7192 OUAGADOUGOU 03, BF, Burkina Faso

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact